Hear AtLast Holdings, Inc. (HRAL) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.35: the stock has moved about 65% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHear AtLast Holdings, Inc. (HRAL) trades at $0.0004. Hear AtLast Holdings, Inc. operates hearing clinics in North America, providing hearing assessments and instruments. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HRAL: HRAL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HRAL against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
HRAL: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Hear AtLast Holdings, Inc. (HRAL) Healthcare & Pipeline Overview
Hear AtLast Holdings, Inc. focuses on the North American hearing clinic market, offering hearing assessments, digital hearing aids, and assistive devices. Operating primarily within the OTC market, the company faces challenges in profitability and market visibility while serving a niche healthcare segment.
What Is the Investment Thesis for HRAL?
Hear AtLast Holdings, Inc. presents a speculative investment opportunity, primarily due to its presence in the growing audiology market. However, the company's negative profit margin of -11725.9% and gross margin of -166.2% raise concerns about its financial sustainability. Growth catalysts include potential expansion of clinic locations and increased adoption of digital hearing aid technology. The company's low beta of 0.35 suggests lower volatility compared to the market. Investors should carefully consider the risks associated with OTC-listed companies and the company's current financial performance before investing.
Based on FMP financials and quantitative analysis
HRAL Key Highlights
Market Cap of $0.00B indicates a micro-cap company with limited market influence.
- P/E Ratio of -0.38 reflects negative earnings, suggesting the company is not currently profitable.
- Profit Margin of -11725.9% highlights significant losses relative to revenue.
- Gross Margin of -166.2% indicates that the cost of goods sold exceeds revenue, raising concerns about the company's pricing strategy and operational efficiency.
- Beta of 0.35 suggests the stock is less volatile than the overall market.
Who Are HRAL's Competitors?
HRAL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| LUCY Innovative Eyewear, Inc. | $0.84 | -3.05% | $5.31M | — |
| FEMY Femasys Inc. | $2.74 | -3.18% | $8.27M | — |
| RGNT Regentis Biomaterials Ltd. | $1.89 | -3.57% | $13.3M | 645-pillar |
| ZJYL Jin Medical International Ltd. | $2.06 | -8.44% | $16.1M | 405-pillar |
| HBIO Harvard Bioscience, Inc. | $8.16 | +0.12% | $36.8M | — |
| MLSS Milestone Scientific Inc. | $0.43 | +3.85% | $38.4M | — |
| POCI Precision Optics Corporation, Inc. | $4.45 | +1.37% | $48.7M | 325-pillar |
| NEPH Nephros, Inc. | $4.52 | 0.00% | $49.1M | 335-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HRAL's Key Strengths?
Established presence in North American hearing clinic market.
- Offers a range of hearing assessment and hearing aid products.
- Expertise in audiology and hearing solutions.
- Historical partnerships with retail locations.
What Are HRAL's Weaknesses?
Negative profit margin and gross margin.
- Limited market capitalization.
- Dependence on retail partnerships.
- OTC market listing may limit investor access.
What Could Drive HRAL Stock Higher?
Potential expansion of telehealth services to reach a broader customer base.
- Development of advanced hearing aid technology to enhance product offerings.
- Strategic partnerships with ENT clinics to increase patient referrals.
What Are the Key Risks for HRAL?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established hearing aid manufacturers.
- Regulatory changes impacting hearing aid sales and reimbursement.
- Negative profit margin and gross margin raise concerns about financial sustainability.
- OTC market listing may limit investor access and increase volatility.
- Economic downturn affecting consumer spending on healthcare.
What Are the Growth Opportunities for HRAL?
- Expansion of Telehealth Services: Hear AtLast can leverage telehealth to offer remote hearing assessments and consultations, expanding its reach to underserved areas and reducing operational costs. The telehealth market is projected to reach $55.6 billion by 2027, presenting a significant growth opportunity. This initiative can be implemented within the next 1-2 years.
- Development of Advanced Hearing Aid Technology: Investing in research and development to create more sophisticated hearing aids with features like noise cancellation and Bluetooth connectivity can attract a wider customer base. The global hearing aid market is expected to reach $10.7 billion by 2028, driven by technological advancements. This is an ongoing opportunity with continuous innovation.
- Strategic Partnerships with ENT Clinics: Collaborating with ear, nose, and throat (ENT) clinics can provide Hear AtLast with a steady stream of referrals and increase brand visibility. Strategic alliances can be formed within the next year, leading to increased patient volume and revenue growth.
- Targeting the Geriatric Population: With the aging global population, there is a growing demand for hearing solutions among seniors. Hear AtLast can tailor its marketing efforts and product offerings to cater to the specific needs of this demographic. The geriatric care market is expanding rapidly, offering a sustainable growth avenue.
- Geographic Expansion within North America: Hear AtLast can expand its clinic network to new locations within North America, particularly in areas with a high concentration of elderly residents. Market research can identify optimal locations for new clinics, with expansion efforts potentially starting within the next 2-3 years.
What Are HRAL's Competitive Advantages?
- Established clinic network in North America.
- Partnerships with retail locations (historically Wal-Mart).
- Brand recognition in local markets.
- Expertise in hearing assessments and hearing aid fitting.
What Does HRAL Do?
Hear AtLast Holdings, Inc., established in 2004 and headquartered in Georgetown, Canada, operates hearing clinics across North America. Originally founded as 226 Music Group, the company rebranded in 2007 to focus on the audiology sector. Hear AtLast specializes in providing hearing assessments and dispensing hearing instruments, including digital hearing aids and assistive listening devices. Their product line also includes essential accessories such as hearing aid wax guards, chargers, cleaners, and sound tubes. A significant part of their early strategy involved operating clinics within Wal-Mart stores; as of March 2010, they had 23 such locations. Today, Hear AtLast continues to serve individuals with hearing impairments, offering solutions to improve their quality of life through better hearing. The company navigates a competitive landscape, focusing on providing accessible hearing care solutions.
What Products and Services Does HRAL Offer?
- Operates hearing clinics in North America.
- Provides hearing assessments to identify hearing loss.
- Offers a range of digital hearing aid instruments.
- Sells assistive-listening devices to improve hearing in specific situations.
- Provides accessories such as hearing aid wax guards, chargers, and cleaners.
- Offers maintenance and repair services for hearing aids.
How Does HRAL Make Money?
- Generates revenue through the sale of hearing aids and assistive-listening devices.
- Provides hearing assessment services for a fee.
- Sells accessories and maintenance products related to hearing aids.
- Operates hearing clinics to provide direct customer interaction and service.
What Industry Does HRAL Operate In?
Hear AtLast Holdings, Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. The industry is characterized by technological advancements in hearing aid devices and increasing demand due to an aging population. Competition includes companies like CDXI, LGBI, MDVLQ, MODC, and MOTS, which offer similar hearing solutions. The market is influenced by factors such as regulatory changes, reimbursement policies, and consumer preferences for discreet and advanced hearing technology.
Who Are HRAL's Key Customers?
- Individuals experiencing hearing loss.
- Seniors seeking hearing solutions.
- Individuals requiring assistive-listening devices for specific needs.
- Customers seeking hearing assessments and consultations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 254 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 44 |
| 2026-08-26 | 44 |
| 2026-08-29 | 44 |
| 2026-09-01 | 44 |
| 2026-09-04 | 44 |
| 2026-09-07 | 44 |
| 2026-09-10 | 44 |
What changed?
The score has stayed at 44.
Over the same 18 days the stock moved +33.3%.
Key Financial Metrics
Return on equity for Hear AtLast Holdings, Inc. stands at 22.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
HRAL Revenue & Earnings Trend
In Q3 FY2025, HRAL generated $5K in top-line revenue, marking a sequential increase of 118.3%. The company recorded a net loss of $299K, with diluted EPS of $0.00.
Company Profile
Hear AtLast Holdings, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Georgetown, CA. The company is led by CEO Peter David Wanner. HRAL has traded publicly since 2009.
Financial Health
Hear AtLast Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
HRAL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established presence in North American hearing clinic market.
- Offers a range of hearing assessment and hearing aid products.
- Expertise in audiology and hearing solutions.
- Historical partnerships with retail locations.
Bear Case
- Negative profit margin and gross margin.
- Limited market capitalization.
- Dependence on retail partnerships.
- OTC market listing may limit investor access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2025 | $5,184 | -$299,123 | $0.00 |
| Q2 FY2025 | $2,375 | -$125,893 | $0.00 |
Q3 FY2025 · filed 31 Dec 2025 · SEC EDGAR →
Based on FMP financials and quantitative analysis
HRAL Latest News
No recent news available for HRAL.
HRAL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HRAL.
Price Targets
Wall Street price target analysis for HRAL.
HRAL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HRAL; grades run from A+ (80-100) to F (below 30).
Leadership: Peter David Wanner
CEO
Peter David Wanner serves as the Chief Executive Officer of Hear AtLast Holdings, Inc. His background includes experience in managing and growing businesses, with a focus on strategic development and operational efficiency. Wanner's leadership aims to drive Hear AtLast towards sustainable growth and profitability within the competitive audiology market. His expertise encompasses business strategy, financial management, and market expansion.
Track Record: Under Peter David Wanner's leadership, Hear AtLast Holdings, Inc. has focused on maintaining its presence in the North American hearing clinic market. Key initiatives include streamlining operations and exploring opportunities for strategic partnerships. Wanner's tenure has been marked by efforts to navigate the challenges of the OTC market and improve the company's financial performance.
HRAL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hear AtLast Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to those listed on major exchanges like NYSE or NASDAQ. This tier typically includes companies with higher risk profiles and speculative investments.
- OTC Tier: OTC Other
- Limited financial disclosure increases investment risk.
- Low trading volume and wide bid-ask spread can lead to price volatility.
- OTC Other listing indicates higher risk compared to major exchanges.
- Potential for delisting or trading suspension due to non-compliance.
- Limited regulatory oversight may increase the risk of fraud or manipulation.
- Verify the company's financial statements and audit reports.
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Analyze the company's competitive positioning and market share.
- Evaluate the company's legal and regulatory compliance.
- Check for any outstanding legal or regulatory issues.
- Consult with a financial advisor to assess the investment risk.
- Established presence in the hearing clinic market.
- Historical partnerships with retail locations.
- CEO with experience in business management.
- Offers a range of hearing assessment and hearing aid products.
- Operating history since 2004.
What Investors Ask About Hear AtLast Holdings, Inc. (HRAL) — Healthcare
Is HRAL a good stock?
Stock Expert AI does not rate HRAL buy, sell or hold. Hear AtLast Holdings, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about HRAL stock?
There is currently no available analyst coverage for Hear AtLast Holdings, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as revenue growth and earnings per share are not readily available.
What are the main risks for HRAL?
The main risks for Hear AtLast Holdings, Inc. include its negative profit margin and gross margin, which raise concerns about its financial sustainability.
What are the key factors to evaluate for HRAL?
Evaluate HRAL on fundamentals, analyst consensus, and risk factors. Hear AtLast Holdings, Inc. presents a speculative investment opportunity, primarily due to its presence in the growing audiology market. Not financial advice.
How frequently does HRAL data refresh on this page?
HRAL's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven HRAL's recent stock price performance?
Hear AtLast Holdings, Inc. (HRAL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in North American hearing clinic market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HRAL overvalued or undervalued right now?
Hear AtLast Holdings, Inc. (HRAL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of HRAL?
Yes, most major brokerages offer fractional shares of Hear AtLast Holdings, Inc. (HRAL) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited and may not be current.
- OTC market investments carry higher risk.
- Analyst coverage is not available.